Effect of adjuvant treatment with Xiyanping injection on the prognosis of viral encephalitis in children: a multicenter retrospective study

Background: Viral encephalitis (VE), a central nervous system disorder with high mortality and disability rates, poses a serious threat to childhood development. Xiyanping injection (XYPI), an andrographolide sulfonate preparation widely used in China, exhibits anti-inflammatory, antiviral, antitumor, antibacterial and neuroprotective properties.

Methods: We conducted a retrospective study of 635 pediatric inpatients with VE who were hospitalized at seven medical centers in China between January 2015 and December 2021. Risk factors for poor prognosis were compared between inpatients treated with XYPI (n = 480) and those without XYPI treatment (n = 155). Propensity score matching was performed to reduce potential confounding. Clinical symptoms, hospitalization costs, complications and sequelae were evaluated simultaneously.

Results: Multivariate Logistic regression identified XYPI treatment as an independent protective factor for poor prognosis (odds ratio [OR] = 0.251, 95% confidence interval [CI]: 0.113–0.559, p < 0.001). XYPI significantly shortened the duration of fever and headache, reduced hospitalization costs, and lower the incidences of respiratory infections, myocardial injury, and sequelae (all p < 0.05).

Conclusion: Adjuvant XYPI therapy may improve clinical outcomes and reduce the economic burden in pediatric VE; however, randomized trials are warranted to validate these findings.

1 Introduction

Viral encephalitis (VE), a widespread infectious disease of the central nervous system, accounts for approximately 20%–50% of encephalitis cases worldwide (Vora et al., 2014). Characterized by high mortality and disability rates, VE represents a major global health burden. It is defined as inflammation of the brain parenchyma caused by neurotropic viruses and presents with diverse clinical manifestations, ranging from mild symptoms to diffuse or focal neurological deficits. Patients may also exhibit nonspecific viral prodromes, including fever, headache, nausea, and vomiting (Venkatesan et al., 2013). Importantly, VE is frequently associated with severe and long-term sequelae such as irreversible neurological damage and cognitive impairment (Mcgrath et al., 1997; Mailles and Stahl, 2009).

The diagnosis of VE requires a comprehensive approach that integrates clinical features, laboratory testing, and epidemiological history. The gold standard for confirmation is the detection of specific viral antigens, antibodies, or nucleic acids in cerebrospinal fluid or brain tissue (Feng et al., 2020). Despite advances in diagnostic techniques, however, the causative virus remains unidentified in 30%–62% of clinically confirmed cases (Yong et al., 2023). A wide range of viruses—including enteroviruses, herpes simplex virus (HSV), epstein–barr virus, human immunodeficiency virus, and other unidentified agents—have been implicated in VE (Vora et al., 2014; George et al., 2014). Among children, HSV encephalitis and enterovirus encephalitis are the most common etiologies (Bloch et al., 2023; Parvez and Ohtsuki, 2022). Pediatric VE imposes a considerable economic burden on both health systems and families (Li et al., 2023).

Supportive care remains the cornerstone of VE management, and approximately 20% of patients require intensive care unit admission (Thakur et al., 2013). Complications such as deep vein thrombosis and epilepsy often demand concurrent treatment (Bradshaw and Venkatesan, 2019; Steiner et al., 2005). Despite the availability of antiviral therapy, patients with HSV encephalitis continue to experience mortality rates of up to 28% and frequently develop severe neurological sequelae (Bradshaw and Venkatesan, 2016). Overall, VE exhibits a mortality rate ranging from 1% to 90% owing to the lack of specific antiviral agents (Ludlow et al., 2016).

In the theoretical framework of traditional Chinese medicine (TCM), VE is not recognized as an independent disease entity. Based on its key clinical manifestations and neurological dysfunction, however, it is classified within the broader category of Warm Disease. The TCM pathogenesis of VE is considered multifactorial, involving disturbances of multiple organ systems, particularly the brain, heart, lungs, liver, and kidneys. This holistic perspective aligns with modern biomedical evidence showing that inadequate viral clearance at the primary infection site can allow dissemination to the central nervous system and other organs, leading to multisystem complications (Yang et al., 2023).

The TCM etiology of VE can be interpreted from two principal perspectives. First, it is attributed to exposure to “epidemic toxins,” a concept closely paralleling the modern biomedical notion of pathogens. Second, it arises from a deficiency of healthy Qi, reflecting an intrinsic weakness in the body’s ability to resist pathogenic invasion. This deficiency, together with an imbalance between Yin and Yang, creates systemic dysfunction that allows pathogenic toxins to ascend and invade the brain orifices, thereby inducing encephalitis (Jia et al., 2016). Emerging evidence supports these concepts: the severity of HSV encephalitis in children is strongly associated with monogenic inborn errors in the Toll-like receptor 3–dependent signaling pathway, which impair the production of key antiviral cytokines such as Interferon-beta and Interferon-lambda—a mechanistic defect analogous to the TCM concept of healthy Qi deficiency (Zhang, 2020). Moreover, neurotropic viruses can disrupt the blood–brain barrier and trigger both adaptive immune responses and trained immunity, culminating in cytokine storm and aggravated neuroinflammation, a process that mirrors the TCM doctrine of Yin–Yang imbalance (Matthews et al., 2025).

TCM provides multiple therapeutic strategies for VE, including herbal decoctions, proprietary Chinese patent medicines, and acupuncture (Wang, 2006). Clinical evidence indicates that formulas such as Changpu Yujin Decoction and Baihu Decoction significantly enhance treatment efficacy in VE (Rao and Han, 2023; Wang et al., 2016). A systematic review of 23 clinical trials demonstrated that Xingnaojing injection combined with conventional therapy improved cure rates, shortened symptom recovery time, and reduced mortality (Cao et al., 2019). Similarly, a meta-analysis of 1,045 cases reported that Angong Niuhuang Pill, when used as an adjunctive therapy, increased the overall effectiveness rate by 17% (Huang et al., 2024). Our previous work also showed that proprietary Chinese medicines effectively improved clinical symptoms and reduced sequelae in pediatric VE (Wang et al., 2024). Acupuncture, used as an adjuvant therapy, has likewise demonstrated clinical benefits; in a rat model of herpes simplex encephalitis, acupuncture improved spatial learning and memory impairments (Jin et al., 2024). Furthermore, the antiviral activities of specific herbal extracts are being increasingly validated. For example, Rhodiola extract disrupts the binding and stability of Japanese encephalitis virus, whereas Artemisia argyi extract damages the integrity of HSV particle membranes, offering new potential therapeutic strategies for viral infections (Lai et al., 2024; Liu et al., 2023).

Xiyanping injection (XYPI), a well-established injectable preparation with a long history of clinical use in China, exhibits broad therapeutic activities, including potent anti-inflammatory, antiviral, and antibacterial effects. XYPI is primarily composed of andrographolide sulfonate (AS). Using high-performance liquid chromatography, Zhan et al. identified four key metabolites of XYPI: andrographolide sulfate ester A, andrographolide sulfate ester B, andrographolide sulfate ester C, and 9-dehydro-17-hydroxyandrographolide (Zhan et al., 2012). Accumulating evidence also indicates that XYPI has additional pharmacological effects, including antitumor and neuroprotective activities. (Lu et al., 2019).

XYPI has been incorporated into the Chinese Pediatric Association guidelines as a first-line therapy for several pediatric infectious diseases, such as viral pneumonia, acute undifferentiated febrile illness, hand-foot-and-mouth disease, and influenza-like illnesses (Wang et al., 2019; Yang et al., 2024). Pharmacokinetic studies in rat models have revealed extensive tissue distribution of XYPI metabolites, with quantifiable concentrations detected in the brain, heart, kidneys, liver, lungs, and spleen (Bera et al., 2014). Moreover, a large-scale real-world clinical study conducted in China demonstrated that XYPI is an effective therapeutic agent for VE, with enhanced efficacy observed when used in combination with conventional chemical drugs (Sheng et al., 2022).

Despite significant advances in neuropharmacological research on XYPI, high-quality clinical evidence supporting its use as an adjuvant therapy for pediatric VE remains scarce. This retrospective study therefore aims to comprehensively assess the benefit–risk profile of XYPI-augmented regimens in the management of pediatric VE, thereby providing an evidence-based foundation for optimizing neuroprotective strategies in this vulnerable population.

2 Materials and methods

2.1 Drug information

XYPI contains only AS and water for injection, with no additional excipients. It has been approved by the China National Medical Products Administration under drug approval number WS-10863-(ZD-0863)-2002 and national drug registration number Z20026249. AS is primarily extracted from Andrographis paniculata (Burm. f.) Nees (Acanthaceae; Andrographidis herba). In this study, all XYPI reagents were supplied by Jiangxi Qingfeng Pharmaceutical Co.,Ltd. The contents of total sulfonates and 17-hydroxy-9-dehydroandrographolide-19-sulfate sodium were quantitatively determined for quality control. Furthermore, chromatographic fingerprint analysis confirmed that their retention times were identical to those of the corresponding reference peaks. The product inspection reports and batch-specific documentation for XYPI are provided in the Supplementary Material.

2.2 Population

Between 2015 and 2021, we conducted a retrospective analysis of 919 pediatric inpatients diagnosed with VE across multiple hospitals, including Beijing Ditan Hospital, Liaocheng Children’s Hospital, the First Affiliated Hospital of Shandong First Medical University, Guangzhou Women and Children’s Medical Center, Shanghai Children’s Medical Center, Wuhan Jinyintan Hospital, and Tianjin Second People’s Hospital.

The inclusion criteria were: (1) age between 0 and 18 years old (2) a diagnosis of VE consistent with the consensus statement of the International Encephalitis Consortium (Venkatesan et al., 2013).

The exclusion criteria were: (1) coexisting bacterial or autoimmune encephalitis; (2) concomitant use of other TCM adjuvant therapies; (3) death on the day of hospitalization; (4) incomplete medical records.

This multicenter clinical study was approved by the Ethics Committee of Beijing Ditan Hospital (Approval No. Jing Di Lun Ke Zi [2018] (027)-03) and conducted in accordance with the ethical principles of the Declaration of Helsinki. As the lcoordinating center, Beijing Ditan Hospital oversaw the study protocol and submitted the approved documentation to the ethics committees of all participating centers for registration. Written informed consent was obtained from both patients and their legal guardians prior to study enrollment. The trial is registered with the Chinese Clinical Trial Registry (ChiCTR1900023284).

2.3 Clinical diagnosis and data collection

VE was defined as an acute alteration in mental status lasting ≥24 h at presentation without an alternative identifiable cause (Venkatesan et al., 2013). This definition additionally required either: (1) neuropathological findings consistent with encephalitis, or (2) acute microbiological or serological evidence of encephalitis from clinical specimens (Venkatesan et al., 2013). In cases of diagnostic uncertainty, consultation with neurology specialists was obtained.

The following data were systematically collected: demographic and epidemiological characteristics; clinical signs and symptoms; results of routine cerebrospinal fluid (CSF) analysis (including protein, glucose, and chloride levels); neuroimaging findings; length of hospital stay; in-hospital complications; and total hospitalization costs.

Adverse drug reactions were monitored and documented throughout hospitalization. Functional outcomes at discharge were assessed using the modified Rankin Scale (mRS). According to established criteria, an mRS score of 0–2 was considered a favorable prognosis, whereas a score of ≥3 indicated a poor prognosis (Saver et al., 2021). All patients were followed for 6 months after discharge, and detailed records of their sequelae were obtained. All data were collected by trained personnel using standardized case report forms and subsequently uploaded to a secure, cloud-based electronic database for centralized management and analysis.

2.4 Treatment

All patients diagnosed with VE received treatment in accordance with established clinical guidelines (Tunkel et al., 2008). Based on neurologist recommendations, empirical antiviral therapy with intravenous acyclovir was administered at a dose of 10 mg/kg every 8 h. Mannitol was given intravenously at 1 g/kg every 8 h to reduce intracranial pressure. Supportive care, including maintenance of fluid and electrolyte balance and regulation of body temperature, was provided as needed. Patients in the XYPI group additionally received XYPI intravenously at a dose of 5–10 mg/kg once daily, with a maximum daily dose not exceeding 250 mg.

2.5 Statistical methods

SPSS 25 (IBM Corp., Armonk, NY, United States of America) and R software version 4.4.1 (R Foundation for Statistical Computing, Vienna, Austria) were used for analysis. The normality of continuous variables was assessed prior to analysis. Variables with a normal distribution were compared using Student’s t-test, whereas non-normally distributed variables were analyzed using the Mann–Whitney U test. Categorical variables were compared using the Chi-square test or Fisher’s exact test, as appropriate. Data are expressed as mean ± standard deviation for normally distributed variables, median (25th–75th percentile) for non-normally distributed variables, and number (%) for categorical variables. To reduce selection bias and estimate the unbiased treatment effect between patients who received XYPI and those who did not, propensity score matching (PSM) was applied. Univariate and multivariate logistic regression analyses were used to calculate odds ratios (ORs) and 95% confidence intervals (CIs) for poor prognosis in patients with VE. The cumulative incidence of poor prognosis was estimated using Kaplan–Meier survival curves, and group differences were evaluated with the log-rank test. P value <0.05 was considered statistically significant.

3 Results

3.1 Baseline characteristics

A total of 635 inpatients were included in the final analysis and classified into the XYPI group (n = 480) or the non-XYPI group (n = 155), as shown in Figure 1. Before PSM, significant differences in baseline characteristics were observed between the two groups. Specifically, the XYPI group exhibited a higher prevalence of headache, whereas the non-XYPI group showed a significantly higher incidence of vertigo, fatigue, convulsions, and respiratory symptoms. CSF analysis revealed that glucose and chloride levels were higher in the non-XYPI group than in the XYPI group. After 1:1 PSM, the baseline clinical characteristics were well balanced between the two groups, as summarized in Table 1.

Figure 1

Figure 1. Flow chart of patient enrollment and selection for pediatric viral encephalitis.

Table 1

Table 1. Clinical characteristics of pediatric viral encephalitis in unmatched and propensity score–matched cohorts.

3.2 Prognostic risk factors

As shown in Table 2, multivariate logistic regression analysis demonstrated that, even after adjusting for potential confounders—including family history, prehospital care, headache, vertigo, convulsions, fatigue, and GCS score—XYPI use was independently associated with a significantly reduced risk of poor prognosis in patients with VE (OR = 0.251, 95% CI: 0.113–0.559, p = 0.001). This analysis also identified vertigo (OR = 4.447, 95% CI: 1.476–13.400, p = 0.009) and fatigue (OR = 2.923, 95% CI: 1.203–7.104, p = 0.006) as significant independent risk factors for poor outcomes, whereas headache (OR = 0.302, 95% CI: 0.127–0.715, p = 0.006) and higher GCS scores (OR = 0.677, 95% CI: 0.552–0.830, p < 0.001) were protective factors.

Table 2

Table 2. Multivariate analysis of risk factors for poor prognosis in patients with viral encephalitis after propensity score matching.

Additionally, a separate multivariate logistic regression analysis of all patients at baseline, adjusting for family history, prehospital care, headache, vertigo, convulsions, fatigue, dgestive symptoms, respiratory symptoms, and GCS score, confirmed that XYPI use remained a significant protective factor against poor prognosis (OR = 0.409, 95% CI: 0.170–0.987, p = 0.047). The detailed results of this analysis are provided in Supplementary Table S1.

3.3 Incidence of poor prognosis

Comprehensive analysis revealed that the incidence of poor prognosis was significantly lower among patients receiving XYPI during hospitalization (9.17%) compared with those in the non-XYPI group (Figure 2A). Consistently, PSM analysis demonstrated that the XYPI group exhibited a markedly lower incidence of poor outcomes (9.93%) than the matched non-XYPI group (23.17%, Figure 2B).

Figure 2

Figure 2. Cumulative incidence of poor prognosis in pediatric viral encephalitis. (A) Unmatched cohort: cumulative incidence of poor prognosis in patients receiving Xiyanping injection versus non-Xiyanping injection treatment (9.17% vs. 24.51%; log-rank test, P < 0.0001). (B) Propensity score–matched cohort: cumulative incidence of poor prognosis in Xiyanping injection versus non-Xiyanping injection groups (9.93% vs. 23.17%; log-rank test, P = 0.002).

3.4 Symptoms, financial burden, and comorbidities

A comprehensive analysis was conducted to evaluate the effects of XYPI treatment on clinical symptoms, economic outcomes, and in-hospital complications. XYPI administration significantly alleviated fever (Figures 3A,B). Although headache duration showed no baseline difference between groups (Figure 3C), XYPI treatment significantly shortened headache duration after matching (Figure 3D).

Figure 3

Figure 3. Violin plots illustrating the effect of Xiyanping injection on symptom duration and hospitalization costs. (A) Duration of fever (unmatched patients); (B) duration of fever (matched patients); (C) duration of headache (unmatched patients); (D) duration of headache (matched patients); (E) hospitalization costs (unmatched patients); (F) hospitalization costs (matched patients). P values: *p < 0.05, **p < 0.01, ***p < 0.001.

Moreover, XYPI therapy was associated with a significant reduction in hospitalization costs. Before matching, the mean cost for patients not receiving XYPI was 1.12-fold higher than that for XYPI-treated patients. After matching, hospitalization costs in the non-XYPI group remained significantly higher than those in the XYPI group (Figures 3E,F; Supplementary Table S2).

All in-hospital complications were carefully recorded. XYPI administration was associated with a lower incidence of respiratory tract infections (Supplementary Figures S1A, S1B) and a reduced risk of myocardial injury (Supplementary Figures S1C, S1D). In contrast, the frequencies of gastrointestinal dysfunction (Supplementary Figures S1E, S1F) and sepsis (Supplementary Figures S1G, S1H) did not differ significantly between groups.

3.5 Drug-related adverse reactions and sequelae

Drug-related adverse events were systematically monitored and recorded in all hospitalized patients, with particular attention to diarrhea, rash, and chills. Compared with patients who did not receive XYPI, those treated with XYPI experienced a significantly lower incidence of chills (Supplementary Figures S2A, S2B) and rash (Supplementary Figures S2C, S2D), both before and after PSM. In contrast, the incidence of diarrhea did not differ significantly between the two groups (Supplementary Figures S2E, S2F).

At the 6-month follow-up, the majority of patients demonstrated favorable recovery after discharge. However, a small subset exhibited residual sequelae, including gait disturbance (n = 3), intellectual disability (n = 3), and epileptic symptoms (n = 2). Notably, the incidence of sequelae was significantly higher in the non-XYPI group compared with the XYPI group (Supplementary Table S3).

4 Discussion

VE is a life-threatening neurological disorder that can lead to death or long-term disability, posing a serious threat to the healthy development of children and underscoring the urgent need for effective and well-tolerated therapeutic strategies. A recent prospective study reported that, after a 2-year follow-up, approximately 67% of patients with VE continued to experience cognitive impairment, fatigue, and other debilitating sequelae, regardless of initial disease severity, highlighting the persistent and pervasive impact of VE on long-term health outcomes (Schwitter et al., 2024).

At present, the treatment of VE remains largely empirical, relying mainly on antimicrobial therapy and supportive care. Although these approaches constitute the standard of care, growing evidence indicates that TCM may offer beneficial adjunctive effects in pediatric VE, highlighting the potential value of developing integrative treatment strategies that combine it with conventional medicine (Tunkel et al., 2008; Wang et al., 2024).

The mRS is a comprehensive and objective measure of functional disability, providing a standardized framework that minimizes subjective bias. Widely used in various neurological disorders, including acute stroke and cerebral small vessel disease, it enables clinicians to reliably assess and monitor functional status and disability levels (Hosoya et al., 2024; Clancy et al., 2024). In this study, patients’ prognoses were systematically evaluated and stratified using the mRS. Our findings demonstrated that XYPI administration was an independent protective factor against poor outcomes, significantly reducing the risk of unfavorable prognosis.

The GCS, one of the earliest tools developed to evaluate impaired consciousness, coma depth, and duration, encompasses three core components: motor responsiveness, verbal performance, and eye opening (Teasdale and Jennett, 1974). It remains one of the most universally adopted instruments for assessing the level of consciousness and is widely applied in neurological disorders such as acute intracranial injury and stroke (Easter et al., 2015). Consistent with previous reports, our study revealed a significant association between GCS scores and prognostic outcomes, demonstrating that lower GCS scores are predictive of poor prognosis in pediatric encephalitis (Feng et al., 2020; Rebecca et al., 2024; Ngan et al., 2024).

Our study demonstrated that XYPI effectively alleviates clinical symptoms and improves patient prognosis, an effect likely attributable to its multifaceted pharmacological activities, including anti-inflammatory, antiviral, and neuroregulatory properties. Previous studies have shown that AS, the principal active component of XYPI, not only directly inhibits adenovirus replication but also enhances host immunity by modulating neutrophil and T-cell function and promoting macrophage phagocytic activity. These immunomodulatory actions facilitate viral clearance and the release of antiviral factors, thereby suppressing viral replication (Zhang J et al., 2021; Li et al., 2025). Moreover, XYPI mitigates cytokine storm through four key mechanisms: inhibition of p38 phosphorylation, suppression of MAPK phosphorylation, reduction of NF-κB phosphorylation, and negative regulation of STAT3 activation (Li et al., 2025).

The neuroprotective potential of XYPI has been demonstrated across diverse preclinical models, confirming its target-organ specificity for the central nervous system. Permeability–surface area product analyses by Zhou et al. revealed that XYPI stabilizes the blood–brain barrier by modulating paracellular transport and attenuating neuroinflammatory cascades (Zhou et al., 2024). Emerging evidence further highlights the dual therapeutic efficacy of XYPI in promoting neurological recovery and exerting neuro-oncological effects, particularly through the modulation of glioma stem cell plasticity (Zhang L et al., 2021; Othman and Mohd, 2022).

Our study also identified a notable finding: the duration of fever was significantly longer in patients who did not receive XYPI. This observation is consistent with the report by Yang et al., which demonstrated that prolonged fever is a risk factor for poor prognosis in VE (Yang et al., 2024). The antipyretic effect of XYPI may be explained by its ability to suppress the release of pyro-inflammatory mediators such as interleukin-1 and tumor necrosis factor-α, while simultaneously reducing the production of positive regulatory factors, including prostaglandin E2 and 5-hydroxytryptamine, within the hypothalamic fever center (Liu et al., 2014; Guo et al., 2012; Peng et al., 2016a; Peng et al., 2016b). By modulating these key mediators, XYPI may attenuate the febrile response, thereby shortening fever duration and potentially improving clinical outcomes in VE.

The precise causal relationships between VE and the development of complex systemic infections, respiratory diseases, and gastrointestinal disorders warrant further investigation (Bohmwald et al., 2018). Notably, our results demonstrated that XYPI significantly reduced the incidence of respiratory tract infections, an effect that may be attributable to its capacity to ameliorate pathological lung changes, alleviate pulmonary edema, and suppress inflammatory cytokine production (Peng et al., 2016a; Christie et al., 2007; Glaser and Bloch, 2020). Moreover, XYPI administration was associated with a lower rate of myocardial injury. Supporting this finding, Zhang et al. reported the efficacy of XYPI in children with myocardial damage based on real-world data from 39 hospitals across China (Zhang X. Y et al., 2021). Preclinical studies further suggest that these cardioprotective effects may involve activation of the peroxisome proliferator-activated receptor-α signaling pathway (Zhang et al., 2024).

VE imposes a substantial economic burden worldwide. Wang et al. reported that encephalitis caused by Chinese flavivirus in children continues to exhibit a high prevalence of severe cases, particularly in rural regions (Wang et al., 2022). Similarly, Tarantola et al. demonstrated that in the Mekong region—a hotspot for VE—the financial burden associated with this disease exceeds the average income of the general population by nearly tenfol (Tarantola et al., 2014). In the United States, the average cost of encephalitis treatment doubled between 1998 and 2010 (Vora et al., 2014). Consistent with these observations, our findings further highlighted the potential of XYPI to alleviate the economic burden of inpatient care.

Although the incidence of sequelae was relatively low in our cohort, VE remains a life-threatening condition in children. Viruses can invade the central nervous system via three primary routes: peripheral nerves connecting to the brain, olfactory neurons within the nasal epithelium, or direct penetration across the blood–brain barrierr (Sun et al., 2024). Such infections can cause irreversible neural injury, resulting in long-lasting neurological sequelae. Notably, XYPI has been reported to reduce the risk of virus-related sequelae, potentially by inhibiting hemagglutinin adsorption and enhancing immune cell activity, thereby strengthening host antiviral defenses (Wen et al., 2015).

The present study, although retrospective in design, provides valuable evidence supporting the potential therapeutic benefits of XYPI in mitigating VE-related sequelae. Nevertheless, high-quality prospective trials are warranted to conclusively establish its efficacy. In addition, the absence of adult VE data limits the generalizability of our findings. Another limitation is the lack of proteomic profiling and dynamic cytokine analyses of cerebrospinal fluid, which precludes a deeper understanding of the mechanisms underlying XYPI’s effects in pediatric VE. Future studies incorporating these molecular approaches are needed to validate the current findings and elucidate the pathways mediating XYPI’s therapeutic action.

5 Conclusion

This study demonstrates that XYPI effectively reduces adverse outcomes, alleviates clinical symptoms, and lessens the economic burden in pediatric patients with VE. However, larger prospective, multicenter trials are warranted to definitively confirm its efficacy and safety.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

Ethics statement

The studies involving humans were approved by the Ethics Committee of Beijing Ditan Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants‘ legal guardians/next of kin. Written informed consent was obtained from the minor(s)’ legal guardian/ next of kin for the publication of any potentially identifiable data included in this article.

Author contributions

WT: Writing – original draft, Software. YC: Writing – original draft, Methodology. HL: Writing – review and editing, Data curation. DW: Writing – review and editing, Methodology, Data curation. ZW: Data curation, Writing – review and editing, Methodology. YL: Writing – review and editing, Data curation. LL: Methodology, Writing – review and editing, Data curation. XY: Software, Writing – review and editing, Methodology. XM: Writing – review and editing, Software. YZ: Software, Writing – review and editing. CM: Writing – review and editing, Software, Methodology. RW: Writing – review and editing, Methodology. QY: Data curation, Methodology, Writing – review and editing. YY: Methodology, Supervision, Writing – review and editing. YZ: Writing – review and editing, Data curation, Methodology. XG: Writing – review and editing, Supervision. WZ: Writing – review and editing, Supervision, Methodology.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by the Major Project of the National Key Technology R&D Program (2017ZX103 05501–005); the High-level Traditional Chinese Medicine Key Subjects Construction Project of the National Administration of Traditional Chinese Medicine—Beijing University of Chinese Medicine, Chinese Medicine Epidemic Disease (zyyzdxk-2023264); the Talents Cultivation Program of the National Administration of Traditional Chinese Medicine (ZYYCXTD-C-202006); and the High-Level Public Health Technical Personnel Construction Project (Discipline Backbone 02-31).

Conflict of interest

The authors declare that this research was performed in the absence of any commercial or financial relationships that could potentially be construed as a conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2025.1632728/full#supplementary-material

References

Bera, R., Ahmed, S. K., Sarkar, L., Sen, T., and Karmakar, S. (2014). Pharmacokinetic analysis and tissue distribution of andrographolide in rat by a validated LC-MS/MS method. Pharm. Biol. 52 (3), 321–329. doi:10.3109/13880209.2013.836544

PubMed Abstract | CrossRef Full Text | Google Scholar

Bloch, K. C., Glaser, C., Gaston, D., and Venkatesan, A. (2023). State of the art: acute encephalitis. Clin. Infect. Dis. 77 (5), e14–e33. doi:10.1093/cid/ciad306

PubMed Abstract | CrossRef Full Text | Google Scholar

Bohmwald, K., Galvez, N., Rios, M., and Kalergis, A. M. (2018). Neurologic alterations due to respiratory virus infections. Front. Cell. Neurosci. 12, 386. doi:10.3389/fncel.2018.00386

PubMed Abstract | CrossRef Full Text | Google Scholar

Bradshaw, M. J., and Venkatesan, A. (2016). Herpes simplex Virus-1 encephalitis in adults: pathophysiology, diagnosis, and management. Neurotherapeutics 13 (3), 493–508. doi:10.1007/s13311-016-0433-7

PubMed Abstract | CrossRef Full Text | Google Scholar

Bradshaw, M. J., and Venkatesan, A. (2019). Emergency evaluation and management of encephalitis and myelitis in adults. Semin. Neurol. 39 (1), 82–101. doi:10.1055/s-0038-1676845

PubMed Abstract | CrossRef Full Text | Google Scholar

Cao, H. J., Liang, S. B., Zhou, W., Wu, J. R., and Zhang, C. L. (2019). Evaluation of the adjunctive effect of xing nao jing injection for viral encephalitis: a systematic review and meta-analysis of randomized controlled trials. Med. Baltim. 98 (15), e15181. doi:10.1097/MD.0000000000015181

PubMed Abstract | CrossRef Full Text | Google Scholar

Christie, L. J., Honarmand, S., Talkington, D. F., Gavali, S. S., Preas, C., Pan, C. Y., et al. (2007). Pediatric encephalitis: what is the role of Mycoplasma pneumoniae? Pediatrics 120 (2), 305–313. doi:10.1542/peds.2007-0240

PubMed Abstract | CrossRef Full Text | Google Scholar

Clancy, U., Arteaga-Reyes, C., Jaime, G. D., Hewins, W., Locherty, R., Valdes, H. M., et al. (2024). Incident infarcts in patients with stroke and cerebral small vessel disease: frequency and relation to clinical outcomes. Neurology 103 (5), e209750. doi:10.1212/WNL.0000000000209750

PubMed Abstract | CrossRef Full Text | Google Scholar

Easter, J. S., Haukoos, J. S., Meehan, W. P., Novack, V., and Edlow, J. A. (2015). Will neuroimaging reveal a severe intracranial injury in this adult with minor head trauma? the rational clinical examination systematic review. JAMA 314 (24), 2672–2681. doi:10.1001/jama.2015.16316

PubMed Abstract | CrossRef Full Text | Google Scholar

Feng, G., Zhou, L., Li, F., Hu, Y., Wang, X., and Tian, X. (2020). Predictors of outcome in clinically diagnosed viral encephalitis patients: a 5-Year prospective study. Biomed. Res. Int. 2020, 2832418. doi:10.1155/2020/2832418

PubMed Abstract | CrossRef Full Text | Google Scholar

George, B. P., Schneider, E. B., and Venkatesan, A. (2014). Encephalitis hospitalization rates and inpatient mortality in the United States, 2000-2010. PLoS One 9 (9), e104169. doi:10.1371/journal.pone.0104169

PubMed Abstract | CrossRef Full Text | Google Scholar

Glaser, C. A., and Bloch, K. C. (2020). Encephalitis: a global problem deserving of a global approach. Clin. Infect. Dis. 70 (12), 2527–2529. doi:10.1093/cid/ciz690

PubMed Abstract | CrossRef Full Text | Google Scholar

Guo, W., Liu, W., Chen, G., Hong, S., Qian, C., Xie, N., et al. (2012). Water-soluble andrographolide sulfonate exerts anti-sepsis action in mice through down-regulating p38 MAPK, STAT3 and NF-κB pathways. Int. Immunopharmacol. 14 (4), 613–619. doi:10.1016/j.intimp.2012.09.002

PubMed Abstract | CrossRef Full Text | Google Scholar

Hosoya, M., Toi, S., Yoshizawa, H., and Kitagawa, K. (2024). Slow gait speed predicts incident dementia, mortality, and long-term functional outcome in cerebral small-vessel disease. J. Alzheimers Dis. 101, 499–508. doi:10.3233/JAD-240304

PubMed Abstract | CrossRef Full Text | Google Scholar

Huang, C., Wang, R., Lv, J., Zheng, N., Wei, Z., Wu, X., et al. (2024). The adjuvant efficacy of angong niuhuang pill in the treatment of viral encephalitis: a meta-analysis of randomized controlled trials. J. Vis. Exp. 206. doi:10.3791/65969

PubMed Abstract | CrossRef Full Text | Google Scholar

Jia, L., Meng, Y., Wang, S., Wang, Q., and Liu, Z. (2016). Etiology and pathogenesis of viral encephalitis. J. Traditional Chin. Med. Res. 29 (10), 9–11.

Google Scholar

Jin, H., Huang, R., Li, Z., Liu, M., Zhao, N., Zhang, H., et al. (2024). Acupuncture improves spatial learning and memory impairment caused by herpes simplex virus type-1 in rats through the p38 MAPK/CREB pathway. J. Physiol. Sci. 74 (1), 49. doi:10.1186/s12576-024-00941-4

PubMed Abstract | CrossRef Full Text | Google Scholar

Lai, Z. Z., Yen, I. C., Hung, H. Y., Hong, C. Y., Lai, C. W., and Lee, Y. M. (2024). In vitro antiviral activity of Rhodiola crenulata extract against zika virus and Japanese encephalitis virus: viral binding and stability. Pharmaceuticals 17 (8), 988. doi:10.3390/ph17080988

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, Q., Wang, R., Xu, H., Zhang, L., Fu, Y., Tian, J., et al. (2023). Epidemiology and disease burden of hospitalized children with viral central nervous system infections in China, 2016 to 2020. Neurol 138, 38–44. doi:10.1016/j.pediatrneurol.2022.09.003

PubMed Abstract | CrossRef Full Text | Google Scholar

Li, Z., Yao, L., Liu, Z., Wang, L., Ruan, H., Shen, Y., et al. (2025). Andrographolide sulfonates and xiyanping: a review of chemical composition, pharmacological activities, clinical applications, and adverse reactions. Pharmaceuticals 18 (2), 183. doi:10.3390/ph18020183

PubMed Abstract | CrossRef Full Text | Google Scholar

Liu, W., Guo, W., Guo, L., Gu, Y., Cai, P., Xie, N., et al. (2014). Andrographolide sulfonate ameliorates experimental colitis in mice by inhibiting Th1/Th17 response. Int. Immunopharmacol. 20 (2), 337–345. doi:10.1016/j.intimp.2014.03.015

PubMed Abstract | CrossRef Full Text | Google Scholar

Liu, P., Zhong, L., Xiao, J., Hu, Y., Liu, T., Ren, Z., et al. (2023). Ethanol extract from Artemisia argyi leaves inhibits HSV-1 infection by destroying the viral envelope. Virol. J. 20 (1), 8. doi:10.1186/s12985-023-01969-5

PubMed Abstract | CrossRef Full Text | Google Scholar

Lu, J., Ma, Y., Wu, J., Huang, H., Wang, X., Chen, Z., et al. (2019). A review for the neuroprotective effects of andrographolide in the central nervous system. Biomed. Pharmacother. 117, 109078. doi:10.1016/j.biopha.2019.109078

PubMed Abstract | CrossRef Full Text | Google Scholar

Ludlow, M., Kortekaas, J., Herden, C., Hoffmann, B., Tappe, D., Trebst, C., et al. (2016). Neurotropic virus infections as the cause of immediate and delayed neuropathology. Acta Neuropathol. 131 (2), 159–184. doi:10.1007/s00401-015-1511-3

PubMed Abstract | CrossRef Full Text | Google Scholar

Mailles, A., and Stahl, J. P.Steering Committee and Investigators Group (2009). Infectious encephalitis in France in 2007: a national prospective study. Clin. Infect. Dis. 49 (12), 1838–1847. doi:10.1086/648419

PubMed Abstract | CrossRef Full Text | Google Scholar

Matthews, R., Sargent, B. F., Mckeever, S., Huang, Y., Ellul, M. A., and Michael, B. D. (2025). Viral encephalitis - update on pathogenesis and treatment. Curr. Opin. Neurol. 38 (4), 388–396. doi:10.1097/WCO.0000000000001384

PubMed Abstract | CrossRef Full Text | Google Scholar

Mcgrath, N., Anderson, N. E., Croxson, M. C., and Powell, K. F. (1997). Herpes simplex encephalitis treated with acyclovir: diagnosis and long term outcome. J. Neurol. Neurosurg. Psychiatry. 63 (3), 321–326. doi:10.1136/jnnp.63.3.321

PubMed Abstract | CrossRef Full Text | Google Scholar

Ngan, T., Tuyet, N. T., Hung, D. T., Cap, N. T., Nguyen, D. M., and Dat, V. Q. (2024). Clinical characteristics and outcomes of patients with Herpes simplex encephalitis in Vietnam: a retrospective study. BMC Infect. Dis. 24 (1), 556. doi:10.1186/s12879-024-09453-3

PubMed Abstract | CrossRef Full Text | Google Scholar

Othman, N. S., and Mohd, A. D. (2022). Andrographolide induces G2/M cell cycle arrest and apoptosis in human glioblastoma DBTRG-05MG cell line via ERK1/2/c-Myc/p53 signaling pathway. Molecules 27 (19), 6686. doi:10.3390/molecules27196686

PubMed Abstract | CrossRef Full Text | Google Scholar

Parvez, M., and Ohtsuki, G. (2022). Acute cerebellar inflammation and related ataxia: mechanisms and pathophysiology. Brain Sci. 12 (3), 367. doi:10.3390/brainsci12030367

PubMed Abstract | CrossRef Full Text | Google Scholar

Peng, S., Gao, J., Liu, W., Jiang, C., Yang, X., Sun, Y., et al. (2016a). Andrographolide ameliorates OVA-Induced lung injury in mice by suppressing ROS-Mediated NF-κB signaling and NLRP3 inflammasome activation. Oncotarget 7 (49), 80262–80274. doi:10.18632/oncotarget.12918

PubMed Abstract | CrossRef Full Text | Google Scholar

Peng, S., Hang, N., Liu, W., Guo, W., Jiang, C., Yang, X., et al. (2016b). Andrographolide sulfonate ameliorates lipopolysaccharide-induced acute lung injury in mice by down-regulating MAPK and NF-κB pathways. Acta Pharm. Sin. B 6 (3), 205–211. doi:10.1016/j.apsb.2016.02.002

PubMed Abstract | CrossRef Full Text | Google Scholar

Rao, L., and Han, J. (2023). Effect of changpu yujin decoction on traditional Chinese medicine syndrome, neurological function and inflam matory factors for severe viral encephalitis. J. Sichuan Traditional Chin. Med. 41 (02), 91–94.

Google Scholar

Rebecca, B., Thomas, M., Abraham, A. M., Yoganathan, S., Jacob, E., Kumar, S., et al. (2024). Acute encephalitis syndrome in children and adolescents: a five-year descriptive study from South India. Indian Pediatr. 61 (5), 413–418. doi:10.1007/s13312-024-3126-z

PubMed Abstract | CrossRef Full Text | Google Scholar

Saver, J. L., Chaisinanunkul, N., Campbell, B., Grotta, J. C., Hill, M. D., Khatri, P., et al. (2021). Standardized nomenclature for modified rankin scale global disability outcomes: consensus recommendations from stroke therapy academic industry roundtable XI. Stroke 52 (9), 3054–3062. doi:10.1161/STROKEAHA.121.034480

PubMed Abstract | CrossRef Full Text | Google Scholar

Schwitter, J., Branca, M., Bicvic, A., Abbuehl, L. S., Suter-Riniker, F., Leib, S. L., et al. (2024). Long-term sequelae after viral meningitis and meningoencephalitis are frequent, Even in mildly affected patients, a prospective observational study. Front. Neurol. 15, 1411860. doi:10.3389/fneur.2024.1411860

PubMed Abstract | CrossRef Full Text | Google Scholar

Sheng, L., Xie, Y., Wang, Z., Li, L., Wei, R., and Liu, Z. (2022). A real world study of xiyanping injection in treatment of viral encephalitis. Chin. Traditional Herb. Drugs 53 (10), 3125–3133.

Google Scholar

Steiner, I., Budka, H., Chaudhuri, A., Koskiniemi, M., Sainio, K., Salonen, O., et al. (2005). Viral encephalitis: a review of diagnostic methods and guidelines for management. Eur. J. Neurol. 12 (5), 331–343. doi:10.1111/j.1468-1331.2005.01126.x

PubMed Abstract | CrossRef Full Text | Google Scholar

Sun, M., Manson, M. L., Guo, T., and de Lange, E. (2024). CNS viral infections-what to consider for improving drug treatment: a plea for using mathematical modeling approaches. CNS Drugs 38 (5), 349–373. doi:10.1007/s40263-024-01082-3

PubMed Abstract | CrossRef Full Text | Google Scholar

Tarantola, A., Goutard, F., Newton, P., de Lamballerie, X., Lortholary, O., Cappelle, J., et al. (2014). Estimating the burden of Japanese encephalitis virus and other encephalitides in countries of the mekong region. Plos Negl. Trop. Dis. 8 (1), e2533. doi:10.1371/journal.pntd.0002533

PubMed Abstract | CrossRef Full Text | Google Scholar

Teasdale, G., and Jennett, B. (1974). Assessment of coma and impaired consciousness. A practical scale. Lancet 2 (7872), 81–84. doi:10.1016/s0140-6736(74)91639-0

PubMed Abstract | CrossRef Full Text | Google Scholar

Thakur, K. T., Motta, M., Asemota, A. O., Kirsch, H. L., Benavides, D. R., Schneider, E. B., et al. (2013). Predictors of outcome in acute encephalitis. Neurology 81 (9), 793–800. doi:10.1212/WNL.0b013e3182a2cc6d

PubMed Abstract | CrossRef Full Text | Google Scholar

Tunkel, A. R., Glaser, C. A., Bloch, K. C., Sejvar, J. J., Marra, C. M., Roos, K. L., et al. (2008). The management of encephalitis: clinical practice guidelines by the infectious diseases society of America. Clin. Infect. Dis. 47 (3), 303–327. doi:10.1086/589747

PubMed Abstract | CrossRef Full Text | Google Scholar

Venkatesan, A., Tunkel, A. R., Bloch, K. C., Lauring, A. S., Sejvar, J., Bitnun, A., et al. (2013). Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium. Clin. Infect. Dis. 57 (8), 1114–1128. doi:10.1093/cid/cit458

PubMed Abstract | CrossRef Full Text | Google Scholar

Vora, N. M., Holman, R. C., Mehal, J. M., Steiner, C. A., Blanton, J., and Sejvar, J. (2014). Burden of encephalitis-associated hospitalizations in the United States, 1998-2010. Neurology 82 (5), 443–451. doi:10.1212/WNL.0000000000000086

PubMed Abstract | CrossRef Full Text | Google Scholar

Wang, Y. (2006). Current diagnosis and treatment of viral encephalitis and advances in integrated traditional Chinese and Western medicine therapy. Chin. J. Integr. Med. Cardio/Cerebrovascular Disease(09), 795–796.

Google Scholar

Wang, K., Zeng, X., He, Y., and Zhao, X. (2016). Modified baihu decoction combined with scopolamine hydrobromide in the treatment of severe hand, foot, and mouth disease complicated with viral encephalitis. J. Tradit. Chin. Med. 44 (03), 108–110. doi:10.19664/j.cnki.1002-2392.2016.03.035

CrossRef Full Text | Google Scholar

Wang, Z., Rong, P., Ma, R., Xie, Y., Ding, Y., Wang, X., et al. (2019). Experts consensus statement on Xiyanping Injection in clinical practice (children). China J. Chin. Materia Medica 44 (14), 2932–2936. doi:10.19540/j.cnki.cjcmm.20190521.502

PubMed Abstract | CrossRef Full Text | Google Scholar

Wang, R., Wang, X., Zhang, L., Feng, G., Liu, M., Zeng, Y., et al. (2022). The epidemiology and disease burden of children hospitalized for viral infections within the family Flaviviridae in China: a national cross-sectional study. Plos Negl. Trop. Dis. 16 (7), e0010562. doi:10.1371/journal.pntd.0010562

PubMed Abstract | CrossRef Full Text | Google Scholar

Wang, P., Chen, Y., Wan, G., Liu, H., Liu, L., Wen, D., et al. (2024). Effects of adjunctive Chinese patent medicine on outcome of viral encephalitis in children: a multicenter retrospective study in China. Phytomedicine 124, 155303. doi:10.1016/j.phymed.2023.155303

PubMed Abstract | CrossRef Full Text | Google Scholar

Wen, T., Xu, W., Liang, L., Li, J., Ding, X., Chen, X., et al. (2015). Clinical efficacy of andrographolide sulfonate in the treatment of severe hand, foot, and mouth disease (HFMD) is dependent upon inhibition of neutrophil activation. Phytother. Res. 29 (8), 1161–1167. doi:10.1002/ptr.5361

PubMed Abstract | CrossRef Full Text | Google Scholar

Yang, D., Li, X. J., Tu, D. Z., Li, X. L., and Wei, B. (2023). Advances in viral encephalitis: viral transmission, host immunity, and experimental animal models. Zool. Res. 44 (3), 525–542. doi:10.24272/j.issn.2095-8137.2023.025

PubMed Abstract | CrossRef Full Text | Google Scholar

Yang, M., Yi, L., Jia, F., Zeng, X., and Liu, Z. (2024). Characteristics and outcome of influenza-associated encephalopathy/encephalitis among children in China. Clinics 79, 100475. doi:10.1016/j.clinsp.2024.100475

PubMed Abstract | CrossRef Full Text | Google Scholar

Yong, H., Pastula, D. M., and Kapadia, R. K. (2023). Diagnosing viral encephalitis and emerging concepts. Curr. Opin. Neurol. 36 (3), 175–184. doi:10.1097/WCO.0000000000001155

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhan, H., Chen, W., Xiao, X., Yang, X., and Luo, Y. (2012). HPLC simultaneous determination of four effective ingredients in Xiyanping injection. J. Pharm. Anal. 32 (01), 140–143. doi:10.16155/j.0254-1793.2012.01.015

CrossRef Full Text | Google Scholar

Zhang, S. Y. (2020). Herpes simplex virus encephalitis of childhood: inborn errors of central nervous system cell-intrinsic immunity. Hum. Genet. 139 (6-7), 911–918. doi:10.1007/s00439-020-02127-5

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhang, S., Ye, Y., Li, Q., Zhao, J., Song, R., Huang, C., et al. (2024). Andrographolide attenuates myocardial ischemia-reperfusion injury in mice by Up-Regulating PPAR-α. Inflammation 48, 2341–2354. doi:10.1007/s10753-024-02193-1

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhang, J., Zheng, Y., Zhao, Y., Zhang, Y., Liu, Y., Ma, F., et al. (2021). Andrographolide ameliorates neuroinflammation in APP/PS1 transgenic mice. Int. Immunopharmacol. 96, 107808. doi:10.1016/j.intimp.2021.107808

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhang, L., Li, L., Wang, Z., Xie, Y., and Yang, Y. (2021). Analysis on clinical medication characteristics of xiyanping injection for myocardial damage and myocarditis based on real world study. J. New Chin. Med. 53 (19), 28–34. doi:10.13457/j.cnki.jncm.2021.19.006

CrossRef Full Text | Google Scholar

Zhang, X. Y., Lv, L., Zhou, Y. L., Xie, L. D., Xu, Q., Zou, X. F., et al. (2021). Efficacy and safety of xiyanping injection in the treatment of COVID-19: a multicenter, prospective, open-label and randomized controlled trial. Phytother. Res. 35 (8), 4401–4410. doi:10.1002/ptr.7141

PubMed Abstract | CrossRef Full Text | Google Scholar

Zhou, X., Li, J., Quan, S., Zhang, X., Gu, L., Hu, M., et al. (2024). Andrographolide improves ApoE4-Mediated blood-brain barrier injury by alleviating inflammation. Mol. Neurobiol. 61 (10), 7950–7967. doi:10.1007/s12035-024-04088-6

PubMed Abstract | CrossRef Full Text | Google Scholar